10-Q: Breeze Holdings Acquisition Corp. Reports Q3 2024 Results Amidst Merger Plans and Going Concern Uncertainty

Breeze Holdings Acquisition Corp. reported a net income of $2.19 million for the third quarter of 2024, while facing ongoing challenges related to its business combination and going concern status.

Summary

• Breeze Holdings Acquisition Corp., a blank check company, released its financial results for the quarter ended September 30, 2024.
• The company reported a net income of $2.19 million for the quarter, a significant improvement compared to a net loss of $1.08 million in the same period last year.
• This quarter's income was primarily driven by a $2.3 million gain in the fair value of warrant liabilities and $135,536 in interest income, offsetting operating costs of $260,084.
• However, for the nine months ended September 30, 2024, the company reported a net loss of $2.72 million, which includes a $1.35 million loss in the fair value of warrant liabilities and $1.84 million in operating costs, partially offset by $476,103 in interest income.
• The company's cash position outside of the trust account is minimal, with only $2, and it has a working capital deficit of $9.8 million.
• Breeze has been extending its deadline to complete a business combination, and has a new merger agreement with YD Biopharma Limited.
• The company's financial statements are prepared under the assumption that it will continue as a going concern, but there is substantial doubt about its ability to do so due to its current financial situation and the need to complete a business combination.
• The company has also been impacted by a 1% excise tax on stock redemptions, resulting in a liability of $87,087 as of September 30, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with a slight negative bias. While there's a positive net income in Q3, the overall financial health, going concern uncertainty, and repeated delays raise significant concerns. The company's reliance on related party loans and the potential need for further capital raises also contribute to the negative sentiment.

Positives

• The company achieved a net income of $2.19 million for the third quarter of 2024, a significant improvement from the net loss in the same period last year.
• The company has secured a new merger agreement with YD Biopharma Limited, which could provide a path forward for the business.

Negatives

• The company has a significant working capital deficit of $9.8 million.
• The company's cash position outside of the trust account is extremely low, with only $2.
• The company has incurred a net loss of $2.72 million for the nine months ended September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has repeatedly extended its deadline to complete a business combination, indicating potential difficulties in finding a suitable target.
• The company is subject to a 1% excise tax on stock redemptions, which could further strain its finances.

Risks

• The company's ability to continue as a going concern is uncertain due to its current financial situation and the need to complete a business combination.
• The company may not be able to complete a business combination within the extended deadline of December 26, 2024.
• The company's low cash position and working capital deficit could hinder its ability to operate effectively.
• The company is exposed to risks related to geopolitical tensions and conflicts, which could impact its ability to complete a business combination.
• The 1% excise tax on stock redemptions could further reduce the company's financial resources.
• The company's internal controls over financial reporting have been identified as ineffective due to a material weakness related to income tax provision.

Future Outlook

The company is seeking to complete a business combination with YD Biopharma Limited, and is seeking shareholder approval to extend the deadline to complete a business combination to June 26, 2025. The company's future is dependent on the successful completion of a business combination.

Management Comments

• Our management, including our Chief Executive Officer, who serves as our principal executive officer and our principal financial officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures.
• Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2024, because of the identified material weakness in our internal control over financial reporting described below.

Industry Context

The company is a special purpose acquisition company (SPAC), which is a type of company that is formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. The SPAC market has been volatile, and many SPACs have struggled to find suitable acquisition targets. The company's challenges in completing a business combination and its going concern uncertainty are not uncommon in the current SPAC environment.

Comparison to Industry Standards

• The company's financial performance is mixed compared to other SPACs. While the company achieved a net income in Q3 2024, many SPACs are still in the pre-revenue stage and are reporting losses.
• The company's working capital deficit is a concern, as many SPACs maintain a stronger cash position to fund operations and due diligence.
• The repeated extensions to the business combination deadline are not uncommon, but they do indicate potential difficulties in finding a suitable target, which is a common challenge for SPACs.
• The company's delisting from Nasdaq and subsequent trading on the OTCQX Best Market is a negative development, as it reduces the company's visibility and access to capital.
• The company's new merger agreement with YD Biopharma Limited is a positive development, but the success of the merger is not guaranteed, and many SPAC mergers have failed to deliver value to shareholders.

Related Party Transactions

• The company has significant related party loans from its Sponsor, totaling $9,284,523 as of September 30, 2024.
• The company pays an affiliate of the Sponsor $5,000 per month for office space, utilities, and administrative support services.
• The Sponsor has agreed to loan the company funds as needed for working capital, and these loans may be converted into warrants at the lender's discretion, although the Sponsor has elected not to convert.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company fails to complete a business combination.
• Employees may be impacted by the uncertainty surrounding the company's future.
• Creditors may be at risk if the company is unable to repay its debts.
• The company's suppliers and customers may be affected by the company's financial instability.

Next Steps

• The company will hold a meeting of its stockholders on December 23, 2024, to approve an extension to consummate a business combination.
• The company will seek to complete its business combination with YD Biopharma Limited.
• The company will need to address its working capital deficit and going concern uncertainty.

Key Dates

Keywords

business combination, SPAC, merger, warrant liabilities, going concern, excise tax, redemption, working capital, financial results, YD Biopharma